Efficacy and Safety of Ensitrelvir in Patients With Mild-to-Moderate Coronavirus Disease 2019: The Phase 2b Part of a Randomized, Placebo-Controlled, Phase 2/3 Study

BACKGROUND: This phase 2b part of a randomized phase 2/3 study assessed the efficacy and safety of ensitrelvir for mild-to-moderate coronavirus disease 2019 (COVID-19) during the Omicron epidemic. METHODS: Patients were randomized (1:1:1) to orally receive ensitrelvir fumaric acid 125 mg (375 mg on...

Descripción completa

Detalles Bibliográficos
Autores principales: Mukae, Hiroshi, Yotsuyanagi, Hiroshi, Ohmagari, Norio, Doi, Yohei, Sakaguchi, Hiroki, Sonoyama, Takuhiro, Ichihashi, Genki, Sanaki, Takao, Baba, Keiko, Tsuge, Yuko, Uehara, Takeki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Major Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10110269/
https://www.ncbi.nlm.nih.gov/pubmed/36477182
http://dx.doi.org/10.1093/cid/ciac933

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10110269/
https://www.ncbi.nlm.nih.gov/pubmed/36477182
http://dx.doi.org/10.1093/cid/ciac933

Ejemplares similares